Ligand Pharmaceuticals | LGND - Trade Debtors


Ligand Pharmaceuticals reported $54.8M in Trade Debtors for its fiscal quarter ending in March of 2026.





Trade Debtors Change Date
Agenus USD 22.44M 1.14M Dec/2025
Amgen USD 9.14B 432M Mar/2026
Anika Therapeutics USD 29.33M 661K Dec/2025
Arrowhead Research USD 15.68M 203.19M Mar/2026
Baxter International USD 1.7B 310M Mar/2026
Bristol-Myers Squibb USD 14.36B 164M Mar/2026
Eli Lilly USD 21.18B 1.02B Mar/2026
Enanta Pharmaceuticals USD 40.16M 1.52M Dec/2024
Enviri Corporation USD 341.34M 27.84M Dec/2025
Gilead Sciences USD 4.74B 172M Mar/2026
GlaxoSmithKline GBP 7.94B 178M Mar/2026
Glaxosmithkline GBP 10.45B 707.81M Dec/2025
Heron Therapeutics USD 89.59M 8.54M Dec/2025
Insmed USD 178.55M 37.7M Mar/2026
Intrexon USD 1.02M 559K Jun/2024
Ionis Pharmaceuticals USD 74M 8M Mar/2026
Karyopharm Therapeutics USD 26.18M 5.6M Dec/2025
Ligand Pharmaceuticals USD 54.8M 6.25M Mar/2026
MacroGenics USD 13.37M 55.86M Dec/2025
Merck USD 11.78B 345M Dec/2025
Pacira USD 125.64M 1.57M Mar/2026
Pfizer USD 16.17B 332M Mar/2026
Rigel Pharmaceuticals USD 28.9M 1.39M Jun/2024
Sangamo BioSciences USD 581K 110K Jun/2024
Veracyte USD 50.11M 5.45M Mar/2026